Fisher E - Search Results

1

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Cohen JA, et al. Among authors: fisher e. Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74. Neurology. 2009. PMID: 19204263 Clinical Trial.

2

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.

Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Rudick RA, et al. Among authors: fisher e. Neurology. 1999 Nov 10;53(8):1698-704. doi: 10.1212/wnl.53.8.1698. Neurology. 1999. PMID: 10563615 Clinical Trial.

3

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.

Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Rudick RA, et al. Among authors: fisher e. Mult Scler. 2000 Dec;6(6):365-72. doi: 10.1177/135245850000600601. Mult Scler. 2000. PMID: 11212130

4

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.

Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Fisher E, et al. Mult Scler. 2000 Dec;6(6):373-7. doi: 10.1177/135245850000600602. Mult Scler. 2000. PMID: 11212131

5

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA. Rudick RA, et al. Among authors: fisher e. Neurology. 2001 May 22;56(10):1324-30. doi: 10.1212/wnl.56.10.1324. Neurology. 2001. PMID: 11376182

6

Disease modifying therapies in multiple sclerosis.

Fox RJ, Fisher E, Rudick R. Fox RJ, et al. Among authors: fisher e. Neurology. 2002 Aug 13;59(3):471-2; author reply 472-3. doi: 10.1212/wnl.59.3.471. Neurology. 2002. PMID: 12177396 No abstract available.

7

Eight-year follow-up study of brain atrophy in patients with MS.

Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Fisher E, et al. Neurology. 2002 Nov 12;59(9):1412-20. doi: 10.1212/01.wnl.0000036271.49066.06. Neurology. 2002. PMID: 12427893 Clinical Trial.

8

Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.

Miller DM, Rudick RA, Baier M, Cutter G, Doughtery DS, Weinstock-Guttman B, Mass MK, Fisher E, Simonian N. Miller DM, et al. Among authors: fisher e. Mult Scler. 2003 Feb;9(1):1-5. doi: 10.1191/1352458503ms888oa. Mult Scler. 2003. PMID: 12617260 Clinical Trial.

9

Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.

Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans-Coutinho M, Clanet M, Radue EW, Kappos L; European rIFN beta-1a in Relapsing MS Dose Comparison Trial Study Group. Hardmeier M, et al. Among authors: fisher e. Arch Neurol. 2003 Dec;60(12):1736-9. doi: 10.1001/archneur.60.12.1736. Arch Neurol. 2003. PMID: 14676048

10

Defining interferon beta response status in multiple sclerosis patients.

Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Rudick RA, et al. Among authors: fisher e. Ann Neurol. 2004 Oct;56(4):548-55. doi: 10.1002/ana.20224. Ann Neurol. 2004. PMID: 15389896 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,140 results

Search Page

Filters